Trial Sponsor

Study Type

         Condition

Intervention Type

National Cancer Institute
S1501

Treatment
Phase 3

Metastatic HER 2+ Breast Cancer

Carvedilol vs. Placebo

National Cancer Institute
EA1151
(TMIST)

Screening
Phase 3

Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer

Tomosynthesis Mammography

National Cancer Institute
MA.39
(TAILOR RT)

Treatment
Phase 3

Low Risk Node Positive Breast Cancer

Regional vs. Whole Breast Radiation or No Radiation

National Cancer Institute
FB-12
(FACT 1)

Treatment
Phase 2 - Open Label

Early Stage HER2 Negative Breast Cancer

An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage Her2-Negative Breast Cancer Patients Selected with a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1) 

National Cancer Institute
A011801

Treatment
Phase 3

Stage I - IIIC HER2+ Breast Cancer with residual disease after neoadjuvant chemotherapy

Trastuzumab Emtanise & Tucatinib vs. Trastuzumab Emtanise alone

National Cancer Institute
A191901

Educational Intervention
Phase 3

Stage I - III, hormone receptor + HER2- Breast Cancer

Motivational counseling and/or text messaging to promote compliance with endocrine therapy

University of Nebraska
iCaRe2

Registry

Breast Cancer (any stage/type)

Risk factor questionnaire and long-term clinical outcomes data

National Cancer Institute
BR007

Treatment
Phase 3

Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer

Breast Radiation Therapy and Endocrine Therapy vs. Endocrine Therapy alone

National Cancer Institute
EAY191-N2

Treatment
Phase 2

Hormone Receptor-Positive Metastatic Breast Cancer

Fulvestrant and Binimetinib

Eli Lilly and Company
Ember4

Treatment
Phase 3

ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence [EMBER-4]

Imlunestrant vs. Standard Endocrine Therapy(Tamoxifen & Anastrozole)

AstraZeneca
TropionBreast03

Treatment
Phase 3

Stage I-III
Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast

Dato-DXd with or without durvalumab when compared with ICT (capecitabine and/or pembrolizumab)

National Cancer Institute
S2010

Treatment
Phase 3

A randomized phase III trial comparing active symptom monitoring plus patient education versus patient education alone to improve persistence with endocrine therapy in young women with Stage I-III breast cancer(ASPEN)

Active symptom monitoring +patient education

National Cancer Institute
S2212

Treatment
Phase 3

Shorter Anthracycline-free Chemo Immunotherapy adapted to pathological response in early triple negative breast cancer (SCARLET), a randomized phase III study

Neoadjuvant Carboplatin/
Paclitaxel/Pembrolizumab
vs
Neoadjuvant Carboplatin/Docetaxel/
Pembrolizumab

AstraZeneca
TropionBreast-04

Treatment
Phase 3

Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Neoadjuvant Datopotamab Deruxtecan Plus Durvalumab/ Adjuvant Durvalumab with or without Chemotherapy

NSABP/Exact Sciences Corporation
EXActDNA-003 B-64

Treatment Phase: Diagnostic Test: ctDNA MRD test

Histologically confirmed invasive carcinoma of the breast

Clinically node positive or if node negative, any one of the following: TNBC or HER2+ subtype HR+/HER2-negative with at least one of the following: i. High tumor grade (G3) ii. Ki67 index of 20% or higher iii. High genomic risk